

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2789138

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
KNOPP NEUROSCIENCES INC.		11/22/2013
RECEIVING PARTY DATA		
Name:	KNOPP BIOSCIENCES LLC	
Street Address:	2100 WHARTON STREET	
Internal Address:	SUITE 615	
City:	PITTSBURGH	
State/Country:	PENNSYLVANIA	
Postal Code:	15203	
PROPERTY NUMBERS Total: 75		
Property Type	Number	
Application Number:	60744540	
Application Number:	60746441	
Application Number:	60747317	
Application Number:	60747318	
Application Number:	60829066	
Application Number:	11733642	
Application Number:	12932540	
Application Number:	13467778	
Application Number:	13722487	
PCT Number:	US2007066342	
Patent Number:	8017598	
Patent Number:	8445474	
Patent Number:	8518926	
Patent Number:	8519148	
Patent Number:	8524695	
Application Number:	60747320	
Application Number:	13862357	
Application Number:	60870009	
Application Number:	60894835	
Application Number:	60979049	

PATENT

Property Type	Number
Application Number:	13942695
Application Number:	60894814
Application Number:	13973987
Application Number:	60894799
Application Number:	13943698
Application Number:	61090094
Application Number:	61113680
Application Number:	13059713
Application Number:	61218659
Application Number:	61267945
Application Number:	61317118
Application Number:	61356439
Application Number:	12819990
Application Number:	13722150
Application Number:	61310240
Application Number:	13582224
Application Number:	61348698
Application Number:	61452076
Application Number:	13699304
Application Number:	61563217
Application Number:	61584111
Application Number:	61579542
Application Number:	61677416
Application Number:	61764940
Application Number:	61771032
Application Number:	61772328
Application Number:	61786236
Application Number:	61886598
Application Number:	61748416
Application Number:	61754444
Application Number:	61845939
Application Number:	61859147
Application Number:	61845944
Application Number:	61859158
Application Number:	61865118
Application Number:	13966229
Application Number:	61754450
Application Number:	61845943
Application Number:	61859155

PATENT

REEL: 032551 FRAME: 0312

Property Type	Number
Application Number:	61793892
Application Number:	61865583
Application Number:	61865589
Application Number:	61865592
Application Number:	61865595
PCT Number:	US2007069044
PCT Number:	US2007087639
PCT Number:	US2008057158
PCT Number:	US2008057059
PCT Number:	US2009054292
PCT Number:	US2010039379
PCT Number:	US2011026989
PCT Number:	US2011038159
PCT Number:	US2012071426
PCT Number:	US2013054804
Application Number:	60894829

CORRESPONDENCE DATA

Fax Number: (412)281-0717

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Phone: 4124545000

Email: docketingpgh@pepperlaw.com

Correspondent Name: PEPPER HAMILTON LLP

Address Line 1: 500 GRANT STREET

Address Line 2: SUITE 5000

Address Line 4: PITTSBURGH, PENNSYLVANIA 15219-2507

ATTORNEY DOCKET NUMBER:	131717.1
NAME OF SUBMITTER:	PAULA J. WATSON
SIGNATURE:	/Paula J. Watson/
DATE SIGNED:	03/27/2014

Total Attachments: 12

source=KnoppAssignment#page1.tif
source=KnoppAssignment#page2.tif
source=KnoppAssignment#page3.tif
source=KnoppAssignment#page4.tif
source=KnoppAssignment#page5.tif
source=KnoppAssignment#page6.tif
source=KnoppAssignment#page7.tif
source=KnoppAssignment#page8.tif
source=KnoppAssignment#page9.tif
source=KnoppAssignment#page10.tif

PATENT

REEL: 032551 FRAME: 0313

source=KnoppAssignment#page11.tif

source=KnoppAssignment#page12.tif

ASSIGNMENT

This ASSIGNMENT ("*Assignment*"), effective November 22, 2013 (the "*Effective Date*"), is by and between Knopp Neurosciences Inc., a corporation organized under the laws of the State of Delaware, (the "*Assignor*") and Knopp Biosciences LLC, a limited liability company organized under the laws of the State of Delaware, (the "*Assignee*").

WHEREAS, Assignor had entered into a License Agreement dated August 23, 2010, as amended May 21, 2012, with Biogen Idec International Holding Ltd. ("*Biogen Idec*") pursuant to which Assignor licensed certain technology, know-how and patents and applications to Biogen Idec for the purpose of developing and commercializing a product that incorporates dextramipexole for any therapeutic or diagnostic purposes, particularly for treating amyotrophic lateral sclerosis (the "*Biogen Idec License Agreement*");

WHEREAS, Biogen Idec announced on January 3, 2013 the results of EMPOWER, a phase 3 clinical trial investigating dextramipexole in people with amyotrophic lateral sclerosis, wherein dextramipexole did not meet its primary clinical endpoint and then discontinued its development of dextramipexole by terminating the Biogen Idec License Agreement effective as of March 18, 2013;

WHEREAS, upon Biogen Idec's termination of the Biogen Idec License Agreement, the rights in the technology, know-how and patents and applications that were previously licensed to Biogen Idec reverted to Assignor;

WHEREAS, the Patent Properties (as defined below) include both issued patents, which are primarily directed to compositions and methods of using dextramipexole for treating neurodegenerative diseases such as amyotrophic lateral sclerosis, and pending applications, and the value of such issued patents and pending applications are either considered to be of little value in light of the EMPOWER results or speculative in nature due to their pendency;

WHEREAS, Assignee is in the business of discovering and developing drugs;

WHEREAS, Assignor desires to sell, assign and transfer to Assignee the patents and applications set forth on Attachment A hereto, including any patents and applications which claim priority to those patents and applications set forth on Attachment A, any patents and applications to which those set forth on Attachment A claim priority, and any continuations, continuations-in-part, divisions, reissues, re-examinations or extensions thereof, and in and to any and all patents of the United States and foreign countries which may be issued for said patents and applications set forth on Attachment A hereto ("*Patent Properties*"); and

WHEREAS, Assignor and Assignee desire to effectuate such assignment of the Patent Properties pursuant to the terms and conditions set forth herein.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties represent, covenant and agree as follows:

1. **Assignment.** Assignor does hereby irrevocably assign, transfer, convey, grant and set over to Assignee, and Assignee accepts any such assignment, transfer, conveyance, grant and set over of, all of Assignor's worldwide and entire right, title and interest in and to the Patent Properties and any and all intellectual property rights inherent in the Patent Properties and appurtenant thereto. Any assignment of rights shall be held and enjoyed by Assignee, its successors and assigns from and after the date of such assignment as fully and entirely as the same would have been held and enjoyed by Assignor had such assignment not been made.

2. **Acceptance of Assignment; Consideration.** Assignee hereby accepts the rights and properties hereby assigned and transferred to it herein, and Assignee shall pay to Assignor a non-refundable assignment fee of \$5,000 within five (5) days of the Effective Date.

3. **Right to Sue for Past Infringement.** Assignor also assigns to Assignee all of Assignor's right, title, interest and standing to collect, assert, or enforce any claim, right, title or interest of any kind under any and all of the Patent Properties, including, without limitation, the right (i) to sue for all past, present and future infringements, misappropriations or other violations of any rights relating thereto; (ii) to settle, defend, compromise and retain proceeds from any actions, suits, or proceedings relating to the transferred and assigned rights, title, interest, and benefits; and (iii) to do all other such acts and things in relation thereto as Assignee, in its sole discretion, deems advisable.

4. **Cooperation.** Assignor agrees to execute, acknowledge and deliver, or cause to be executed, acknowledged and delivered, such further instruments and documents and to perform such further acts as may be reasonably requested by Assignee to effectuate more fully the transactions contemplated by this Assignment.

5. **Entire Agreement.** This Assignment contains the entire agreement of the parties with respect to the subject matter of this Assignment. No prior agreement or understanding pertaining to any such matter shall be effective. This Assignment may only be modified in a written instrument executed by the parties.

6. **Binding Assignment.** This Assignment shall be binding upon and inure to the benefit of each of the parties hereto, their successors and assigns.


7. **Governing Law.** This Assignment shall be governed by and construed under the laws of the Commonwealth of Pennsylvania, excluding any conflicts of laws rule or principle that might refer the governance or construction of this Assignment to the law of another jurisdiction.

8. **Severability.** If any provision of this Assignment shall be deemed invalid or unenforceable by any court of competent jurisdiction, then such portion shall be deemed severed, and the remainder thereof shall be enforceable in accordance with its terms.

9. **Counterparts.** This Assignment may be executed in counterparts and by facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties hereto have caused this Assignment to be duly executed.

Knopp Neurosciences Inc.
Assignor

By: 
Name:
Title:


ACKNOWLEDGMENT

STATE OF Pennsylvania)
) SS.
COUNTY OF Allegheny)


On this 22 day of November, 2013, before me, a Notary Public, personally appeared Michael Bozik, to me known to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

S E A L

Notary Public



My commission expires 9/17/17



[Signature Page to Assignment]

PATENT
REEL: 032551 FRAME: 0317

Knopp Biosciences LLC
Assignee

By: *M. Bozik*
Name:
Title:

ACKNOWLEDGMENT

STATE OF Pennsylvania)
) SS.
COUNTY OF Allegheny)


On this 22 day of November, 2013, before me, a Notary Public, personally appeared Michael Bozik, to me known to be the person named in and who executed the above instrument, and acknowledged to me that he executed the same for the uses and purposes therein set forth.

S E A L

Notary Public

Alex Greif

My commission expires 9/17/17



[Signature Page to Assignment]

ATTACHMENT A

Patent Properties

Reference No.	Country	Application/Patent No.	Filing Date	Title	Status
	U.S.	60/744,540	4/10/2006	Pramipexole Enantiomer for the Treatment of Macular Degeneration	Expired
PH 100	U.S.	60/746,441	5/4/2006	Tetrahydrobenzothiazoles and Uses Thereof	Expired
PH 200	U.S.	60/747,317	5/16/2006	Tetrahydrobenzothiazoles and Uses Thereof	Expired
PH 300	U.S.	60/747,318	5/16/2006	Tetrahydrobenzothiazoles and Uses Thereof	Expired
PH 600	U.S.	60/829,066	10/11/2006	Compositions and Methods of Treating and Preventing Inflammatory Disorders	Expired
PH 101	U.S.	11/733,642	4/10/2007	Compositions and Methods of Using R(+) Pramipexole	Abandoned
PH 111	U.S.	12/932,540	2/28/2011	Compositions and Methods of Using R(+) Pramipexole	Abandoned
PH 121	U.S.	13/467,778	5/9/2012	Compositions and Methods of Using R(+) Pramipexole	Abandoned
PH 131	U.S.	13/722,487	12/20/12	Compositions and Methods of Using R(+) Pramipexole	Pending
PH 102	PCT	US07/066342	4/10/2007	Compositions and Methods of Using R(+) Pramipexole	Expired; NS not entered
PH 400	U.S.	60/747,320	5/16/2006	Pramipexole Formulations for the Treatment of Parkinson's Disease	Expired
PH 401	U.S.	8,017,598 (11/749,497)	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Granted 9/13/11;
PH 411	U.S.	8,445,474 (13/204,351)	8/5/2011	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Granted 5/21/13
PH 421	U.S.	13/862,357	4/12/1013	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending;
PH 402	PCT	US07/069044	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Expired; NS filed
PH 407	Australia	2007253899	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending;
PH 405	Canada	2652251	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending;
PH 408	China	200780017918.5 (200780017918.5)	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Granted 4/27/11;

Reference No.	Country	Application/Patent No.	Filing Date	Title	Status
PH 428	China	201110047482.2	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending
PH 403	Europe	2026803 (07797504.3)	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Granted 12/21/11 Validated in BE, DK, FR, DE, GR, IE, IT, NL, PL, ES, SE, CH, TR, GB
PH 413	Europe	11186875.8	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending;
PH 423	Europe	12163888.6	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending;
PH 453	Europe	12163947.0	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending
PH 429	Hong Kong	12101721.0	2/21/2012	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending;
PH 449	Hong Kong	12111219.7	11/7/2012	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending;
PH 418	Israel	195256	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Abandoned
PH 404	Japan	2009-511221	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Pending;
PH 409	South Korea	10-2008-7030672	5/16/2007	Compositions of R(+) and S(-) Pramipexole and Methods of Using the Same	Abandoned
PH 700	U.S.	60/870,009	12/14/2006	Compositions and Methods of Using R(+) Pramipexole	Expired
PH 710	U.S.	60/894,835	3/14/2007	Compositions and Methods of Using R(+) Pramipexole	Expired
PH 720	U.S.	60/979,049	10/10/2007	Compositions and Methods of Using (R)-Pramipexole	Expired
PH 701	U.S.	8,518,926 (11/957,157)	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Granted 8/27/13
PH 711	U.S.	13/942,695	07/15/2013	Compositions and Methods of Using (R)-Pramipexole	Pending
PH 702	PCT	US07/087639	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Expired; NS entered
PH 707	Australia	2007333050	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending
PH 717	Australia	2013209376	7/29/2013	Compositions and Methods of Using (R)-Pramipexole	Pending
PH 708	Brazil	PI0718740-8	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending; exam requested 9/3/10
PH 705	Canada	2672596	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;

Reference No.	Country	Application/Patent No.	Filing Date	Title	Status
PH 709	China	200780051371.0	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 738	China	201210258834.3	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 703	Europe	07855182.7	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 713	Europe	12164067.6	4/13/2012	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 723	Europe	12164060.1	4/13/2012	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 729	Hong Kong	10102538.3	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 739	Hong Kong	13102191.8	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 749	Hong Kong	13102192.7	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 718	India	1316/MUMNP/2009	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 719	Israel	199339	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 704	Japan	2009-541622	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 728	Russian Federation	2009126742	12/14/2007	Compositions and Methods of Using (R)-Pramipexole	Granted;
PH 500	U.S.	60/894,829	3/14/2007	Methods of Synthesizing and Purifying R(+) and S(-) Pramipexole	Expired
PH 800	U.S.	60/894,814	3/14/2007	Methods of Enantiomerically Purifying Chiral Compounds	Expired
PH 501	U.S.	8,519,148 (12/049,235)	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Granted 8/27/13
PH 511	U.S.	13/973,987	8/22/2013	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Pending
PH 502	PCT	US08/057158	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Expired; NS entered
PH 507	Australia	2008224844	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Granted 11/22/12;
PH 517	Australia	2012245169		Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Abandoned
PH 505	Canada	2681110	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Abandoned
PH 508	China	200880015920.3	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Abandoned
PH 503	Europe	08732306.9	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Pending;
PH 529	Hong Kong	10109206.9	9/27/2010	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Abandoned
PH 518	India	1902/MUMNP/2009	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Abandoned
PH 509	Israel	200925	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Abandoned

Reference No.	Country	Application/Patent No.	Filing Date	Title	Status
PH 504	Japan	2009-553834	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Abandoned
PH 519	Russian Federation	2454409 (2009137925)	3/14/2008	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Granted 6/27/12
PH 900	U.S.	60/894,799	3/14/2007	Modified Release Formulations and Methods of Using R(+) Pramipexole	Expired
PH 901	U.S.	8,524,695 (12/048,890)	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Granted 9/3/2013
PH 911	U.S.	13/943,698	07/16/2013	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Pending
PH 902	PCT	US08/057059	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Expired; NS entered
PH 907	Australia	2008224869	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Abandoned
PH 917	Australia	2012205273	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Pending;
PH 905	Canada	2680800	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Abandoned
PH 908	China	200880015896.3	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Abandoned
PH 903	Europe	08743922.0	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Pending;
PH 929	Hong Kong	10108126.8	8/25/2010	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Abandoned
PH 909	Israel	200926	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Pending;
PH 904	Japan	2009-553814	3/14/2008	Modified Release Formulations of (6R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazole-diamine and Methods of Using the Same	Pending;
PH 1000	U.S.	61/090,094	8/19/2008	Compositions and Methods of Using (R)-Pramipexole	Expired
PH 1100	U.S.	61/113,680	11/12/2008	Compositions and Methods of Using (R)-Pramipexole	Expired
PH 1002	PCT	US09/054292	8/19/2009	Compositions and Methods of Using (R)-Pramipexole	Expired; NS filed

Reference No.	Country	Application/Patent No.	Filing Date	Title	Status
PH 1003	EP	09808760.4	8/19/2009	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 1029	Hong Kong	11113771.5	12/15/2011	Compositions and Methods of Using (R)-Pramipexole	Pending
PH 1001	U.S.	13/059,713	8/19/2009	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 1005	Canada	2734491	8/19/2009	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 1018	China	200980141639.9	8/19/2009	Compositions and Methods of Using (R)-Pramipexole	Abandoned
PH 1019	India	512/MUMNP/2011	8/19/2009	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 1004	Japan	2011-523958	8/19/2009	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 1028	South Korea	10-2011-7006213	8/19/2009	Compositions and Methods of Using (R)-Pramipexole	Pending;
PH 1300	U.S.	61/218,659	6/19/2009	Compositions and Methods For Treating ALS	Expired
PH 1310	U.S.	61/267,945	12/9/2009	Compositions and Methods For Treating ALS	Expired
PH 1320	U.S.	61/317,118	3/24/2010	Compositions and Methods For Treating ALS	Expired
PH 1330	U.S.	61/356,439	6/18/2010	Compositions and Methods For Treating ALS	Expired
PH 1301	U.S.	12/819,990	6/21/2010	Compositions and Methods For Treating ALS	Abandoned;
PH 1311	U.S.	13/722,150	12/20/12	Compositions and Methods For Treating ALS	Pending;
PH 1307	AU	2010262970	6/21/2010	Compositions and Methods For Treating ALS	Abandoned
PH 1308	BR	PI1010084-9	6/21/2010	Compositions and Methods For Treating ALS	Pending;
PH 1305	CA	2765876	6/21/2010	Compositions and Methods For Treating ALS	Abandoned;
PH 1316	CL	3191-2011	6/21/2010	Compositions and Methods For Treating ALS	Abandoned
PH 1329	CO	11-178.793	6/21/2010	Compositions and Methods For Treating ALS	Pending;
PH 1318	CN	201080036674.7	6/21/2010	Compositions and Methods For Treating ALS	Pending;
PH 1303	EP	10790329.6	6/21/2010	Compositions and Methods For Treating ALS	Published;
PH 1338	HK	12109559.0	6/21/2010	Compositions and Methods for Treating ALS	Pending)

Reference No.	Country	Application/Patent No.	Filing Date	Title	Status
PH 1319	IN	92/MUMNP/2012	6/21/2010	Compositions and Methods For Treating ALS	Abandoned
PH 1304	JP		6/21/2010	Compositions and Methods For Treating ALS	Pending;
PH 1306	MX	Mx/a/2011/013577	6/21/2010	Compositions and Methods For Treating ALS	Pending
PH 1328	RU	2012101792	6/21/2010	Compositions and Methods For Treating ALS	Abandoned
PH 1302	PCT	US10/039379	6/21/2010	Compositions and Methods For Treating ALS	Expired; NS filed
PH 1500	U.S.	61/310,240	3/3/2010	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Expired
PH 1502	PCT	US11/26989	3/3/2011	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Expired; NS filed
PH 1503	EP	11708371.7	3/3/2011	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Pending;
PH 1501	U.S.	13/582,224	8/31/12	Synthesis of Chirally Purified Substituted Benzothiazole Diamines	Pending;
PH 1600	U.S.	61/348,698	5/26/2010	Compounds and Methods of Modulating Mitochondrial ATP Synthase	Expired
PH 2000	U.S.	61/452,076	3/11/2011	Compounds and Methods of Modulating Mitochondrial Bioenergetic Efficiency Through an Interaction with ATP Synthase (Complex V) and Its Subunits	Expired
PH 1602	PCT	US11/038159	5/26/2011	Compounds and Methods of Modulating Mitochondrial Bioenergetic Efficiency Through an Interaction with ATP Synthase (Complex V) and Its Subunits	Expired; NS filed
PH 1601	U.S.	13/699,304	11/20/2012	Compounds and Methods of Modulating Mitochondrial Bioenergetic Efficiency Through an Interaction with ATP Synthase (Complex V) and Its Subunits	Pending;
PH 2100	U.S.	61/563,217	11/23/2011	Methods (Knopp only MOA)	Abandoned
PH 2200	U.S.	61/584,111	1/6/2012	Compositions of R(+) and S(-) Pramipexole and Methods for Using the Same	Abandoned
BI X0691US001/ 321395 PH 2400	U.S.	61/579,542	12/22/2011	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis (Phase I new dose)	Expired
BI X0691WO001/ 335246 PH 2402	PCT	PCT/US12/71426	12/21/2012	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis	Pending;
PH 2500	U.S.	61/677,416	7/30/2012	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis (EMPOWER Manuscript)	Abandoned

Reference No.	Country	Application/Patent No.	Filing Date	Title	Status
PH 3000	U.S.	61/764,940	2/14/13	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis in Responders	Pending
PH 3010	U.S.	61/771,032	2/28/13	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis in Responders	Pending
PH 3020	U.S.	61/772,328	3/4/13	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis in Responders	Pending
PH 3030	U.S.	61/786,236	3/14/13	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis in Responders	Pending
PH 3040	U.S.	61/886,598	10/3/13	Compositions and Methods for Treating Amyotrophic Lateral Sclerosis in Responders	Pending
PH 3100	U.S.	61/748,416	1/2/13	Modulation of gC1qBp for the Treatment of Neurodegenerative Disease	Pending
PH 3200	U.S.	61/754,444	1/18/13	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3210	U.S.	61/845,939	07/12/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3220	U.S.	61/859,147	07/26/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3500	U.S.	61/845,944	07/12/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3510	U.S.	61/859,158	07/26/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3520	U.S.	61/865,118	08/12/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3501	U.S.	13/966,229	08/13/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3502	PCT	US13/054804	08/13/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending;
PH 3300	U.S.	61/754,450	1/18/13	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3310	U.S.	61/845,943	07/12/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 3320	U.S.	61/859,155	07/26/2013	Compositions and Methods for Treating Conditions Related to Increase Eosinophils	Pending
PH 2700	U.S.	61/793,892	3/15/13	Imidazol[4,5-B]Pyridin-2-yl Amides as Kv7 Channel Activators	Pending
PH3700	U.S.	61/865,583	8/15/13	Compositions and methods for treating chronic idiopathic urticaria	Pending

Reference No.	Country	Application/Patent No.	Filing Date	Title	Status
PH3710	U.S.	61/865,589	8/15/13	Compositions and methods for treating chronic idiopathic urticaria	Pending
PH3800	U.S.	61/865,592	8/15/13	Compositions and methods for treating multiple myeloma	Pending
PH3810	U.S.	61/865,595	8/15/13	Compositions and methods for treating multiple myeloma	Pending